The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: Update 2012

Diagnostic Microbiology and Infectious Disease

Volumn 73, Issue 4, 2012, Pages 293-300

  Azie, Nkechi ^a   Neofytos, Dionissios ^b   Pfaller, Michael ^c   Meier Kriesche, Herwig Ulf ^a   Quan, Shun Ping ^a   Horn, David ^d  

^a Astellas Pharma Global Development   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c JMI LABORATORIES   (United States)

^d David Horn LLC   (United States)

Author keywords

Aspergillus; Candida; Invasive fungal infections; Mucormycetes

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ASPERGILLUS; CANDIDA; CANDIDIASIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DIMORPHIC FUNGAL INFECTION; DISEASE REGISTRY; DISEASE SURVEILLANCE; FEMALE; FUNGUS CULTURE; FUNGUS IDENTIFICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; MUCORMYCOSIS; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC MYCOSIS;

ANTIFUNGAL AGENTS; HUMANS; INTERNATIONAL COOPERATION; MICROBIOLOGICAL TECHNIQUES; MYCOSES; NORTH AMERICA; SURVIVAL ANALYSIS;

EID: 84863745855     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.06.012     Document Type: Review

References (72)

1. Anaissie E.J. Trial design for mold-active agents: time to break the mold - aspergillosis in neutropenic adults. Clin Infect Dis 2007, 44:1298-1306.
2. Anaissie E.J., Rex J.H., Uzun O., Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998, 104:238-245.
3. Arendrup M.C., Bruun B., Christensen J.J., Fuursted K., Johansen H.K., Kjaeldgaard P., et al. National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol 2011, 49:325-334.
4. Ascioglu S., Rex J.H., de Pauw B., Bennett J.E., Bille J., Crokaert F., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002, 34:7-14.
5. Baddley J.W., Winthrop K.L., Patkar N.M., Delzell E., Beukelman T., Xie F., et al. Geographic distribution of endemic fungal infections among older persons, United States. Emerg Infect Dis 2011, 17:1664-1669.
6. Borras R., Roselló P., Chilet M., Bravo D., de Lomas J.G., Navarro D. Positive result of the Aspergillus galactomannan antigen assay using bronchoalveolar lavage fluid from a patient with an invasive infection due to Lichtheimia ramosa. J Clin Microbiol 2010, 48:3035-3036.
7. Chen S., Slavin M., Nguyen Q., Marriott D., Playford E.G., Ellis D., et al. Active surveillance for candidemia, Australia. Emerg Infect Dis 2006, 12:1508-1516.
8. Colombo A.L., Nucci M., Park B.J., Nouér S.A., Arthington-Skaggs B., da Matta D.A., et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006, 44:2816-2823.
9. Cummings J.R., Jamison G.R., Boudreaux J.W., Howles M.J., Walsh T.J., Hayden R.T. Cross-reactivity of non-Aspergillus fungal species in the Aspergillus galactomannan enzyme immunoassay. Diagn Microbiol Infect Dis 2007, 59:113-115.
10. Dalle F., Charles P.E., Blanc K., Caillot D., Chavanet P., Dromer F., et al. Cryptococcus neoformans galactoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus galactomannan. J Clin Microbiol 2005, 43:2929-2931.
11. Davis J.A., Horn D.L., Marr K.A., Fishman J.A. Central nervous system involvement in cryptococcal infection in individuals after solid organ transplantation or with AIDS. Transpl Infect Dis 2009, 11:432-437.
12. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
13. Fishman J., Anaissie E., Pfaller M.A., Marr K.A., Olyaei A., Horn D.L., et al. An introduction to the Prospective Antifungal Therapy Alliance 2005.
14. Fishman J.A. Infection in solid-organ transplant recipients. N Engl J Med 2007, 357:2601-2614.
15. TM) 2005.
16. Fridkin S.K., Kaufman D., Edwards J.R., Shetty S., Horan T. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 2006, 117:1680-1687.
17. Giacchino M., Chiapello N., Bezzio S., Fagioli F., Saracco P., Alfarano A., et al. Aspergillus galactomannan enzyme-linked immunosorbent assay cross-reactivity caused by invasive Geotrichum capitatum. J Clin Microbiol 2006, 44:3432-3434.
18. Gudlaugsson O., Gillespie S., Lee K., Vande Berg J., Hu J., Messer S., et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003, 37:1172-1177.
19. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.
20. Horn D., Fishman J., Anaissie E., Steinbach W., Marr K., Pfaller M., et al. PATH Alliance: a comprehensive, prospective registry of patients with invasive fungal infections 2006.
21. Horn D., Neofytos D., Anaissie E., Fishman J., Steinbach W., Olyaei A., et al. PATH Alliance Registry: review of 1214 patients with candidemia 2007.
22. Horn D., Neofytos D., Anaissie E., Fishman J., Steinbach W., Olyaei A., et al. Review of 2019 patients with candidemia through the PATH Alliance Registry 2008.
23. TM Alliance database to measure adherence to IDSA guidelines for the therapy of candidemia 2006.
24. Horn D., Neofytos D., Fishman J.A., Steinbach W.J., Anaissie E.J., Marr K.A., et al. Invasive fungal infections in 1710 patients from the PATH Alliance: epidemiology and outcomes 2007.
25. Horn D., Neofytos D., Marr K., Anaissie E., Pfaller M., Steinbach W., et al. 7483 invasive fungal infections in 6764 patients from the PATH Alliance Registry (2004-2008) 2009.
26. Horn D., Neofytos D., Olyaei A., Anaissie E., Steinbach W., Marr K., et al. Invasive fungal infections in 3720 patients from the PATH Alliance: an update from a comprehensive, prospective registry 2008.
27. Horn D., Neofytos D., Steinbach W., Anaissie E., Fishman J., Olyaei A., et al. Review of 12 patients with Aspergillus osteomyelitis identified by the PATH Alliance Registry 2008.
28. Horn D.L., Fishman J.A., Steinbach W.J., Anaissie E.J., Marr K.A., Olyaei A.J., et al. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis 2007, 59:407-414.
29. Horn D.L., Neofytos D., Anaissie E.J., Fishman J.A., Steinbach W.J., Olyaei A.J., et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the Prospective Antifungal Therapy Alliance Registry. Clin Infect Dis 2009, 48:1695-1703.
30. Horn D.L., Neofytos D., Fishman J., Steinbach W., Anaissie E., Marr K.A., et al. Use of the PATH Alliance database to measure adherence to IDSA guidelines for the therapy of candidemia. Eur J Clin Microbiol Infect Dis 2007, 26:907-914.
31. Horn D.L., Sae-Tia S., Neofytos D. Aspergillus osteomyelitis: review of 12 cases identified by the PATH Alliance Registry. Diagn Microbiol Infect Dis 2009, 63:384-387.
32. Kappe R., Schulze-Berge A. New cause for false-positive results with the Pastorex aspergillus antigen latex agglutination test. J Clin Microbiol 1993, 31:2489-2490.
33. Klevay M.J., Horn D., Neofytos D., Pfaller M., Diekema D.J. Empiric treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection. Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America 46th Annual Meeting. Washington, D.C. 2008.
34. Klevay M.J., Horn D.L., Neofytos D., Pfaller M.A., Diekema D.J. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis 2009, 64:152-157.
35. Kollef M.H., Napolitano L.M., Solomkin J.S., Wunderink R.G., Bae I.G., Fowler V.G., et al. Health care-associated infection (HAI): a critical appraisal of the emerging threat-Proceedings of the HAI Summit. Clin Infect Dis 2008, 47(Suppl. 2):S55-S99.
36. Kontoyiannis D.P., Marr K.A., Park B.J., Alexander B.D., Anaissie E.J., Walsh T.J., et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010, 50:1091-1100.
37. Kullberg B.J., Sobel J.D., Ruhnke M., Pappas P.G., Viscoli C., Rex J.H., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005, 366:1435-1442.
38. Kuse E.R., Chetchotisakd P., da Cunha C.A., Ruhnke M., Barrios C., Raghunadharao D., et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007, 369:1519-1527.
39. Lockhart S.R., Iqbal N., Etienne K.A., Ahlquist A.M., Farley M., Baughman W., et al. Antifungal susceptibility of Candida isolates collected during population-based candidemia surveillance in Atlanta, GA and Baltimore, MD, 2008. Abstract M-1927 2009.
40. Marr K.A., Schlamm H., Rottinghaus S.T., Jagannatha S., Bow E.J., Wingard J.R., et al. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis 2012.
41. Méan M., Marchetti O., Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care 2008, 12:204.
42. Mora-Duarte J., Betts R., Rotstein C., Colombo A.L., Thompson-Moya L., Smietana J., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002, 347:2020-2029.
43. Morgan J., Meltzer M.I., Plikaytis B.D., Sofair A.N., Huie-White S., Wilcox S., et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005, 26:540-547.
44. Morris A., Wei K., Afshar K., Huang L. Epidemiology and clinical significance of Pneumocystis colonization. J Infect Dis 2008, 197:10-17.
45. Neofytos D., Fishman J.A., Horn D., Anaissie E., Chang C.H., Olyaei A., et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010, 12:220-229.
46. Neofytos D., Horn D., Anaissie E., Steinbach W., Olyaei A., Fishman J., et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009, 48:265-273.
47. Neofytos D., Horn D., Marr K., Steinbach W., Anaissie E., Olyaei A., et al. PATH Alliance registry: review of invasive fungal infections in 228 solid organ transplant recipients 2007.
48. Neofytos D., Horn D.L., Anaissie E., Steinbach W., Olyaei A., Pfaller M., et al. PATH Alliance Registry: review of invasive fungal infections in 217 stem cell recipients 2007.
49. Nieto-Rodriguez J.A., Kusne S., Mañez R., Irish W., Linden P., Magnone M., et al. Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Ann Surg 1996, 223:70-76.
50. Nivoix Y., Velten M., Letscher-Bru V., Moghaddam A., Natarajan-Amé S., Fohrer C., et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008, 47:1176-1184.
51. Nolla-Salas J., Sitges-Serra A., León-Gil C., Martínez-González J., León-Regidor M.A., Ibáñez-Lucía P., et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 1997, 23:23-30.
52. Olyaei A.J., Strasfeld L., Horn D.L., Anaissie E.J., Steinbach W.J., Marr K.A., et al. Dosing of antifungal therapy in dialysis dependant patients 2008.
53. Pagano L., Caira M., Candoni A., Offidani M., Fianchi L., Martino B., et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006, 91:1068-1075.
54. Pappas P.G., Alexander B.D., Andes D.R., Hadley S., Kauffman C.A., Freifeld A., et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010, 50:1101-1111.
55. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
56. Pappas P.G., Rotstein C.M., Betts R.F., Nucci M., Talwar D., De Waele J.J., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007, 45:883-893.
57. Park B.J., Pappas P.G., Wannemuehler K.A., Alexander B.D., Anaissie E.J., Andes D.R., et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 2011, 17:1855-1864.
58. Perlroth J., Choi B., Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 2007, 45:321-346.
59. Pfaller M.A., Diekema D.J. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010, 36:1-53.
60. Poikonen E., Lyytikäinen O., Anttila V.J., Ruutu P. Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003, 9:985-990.
61. Procop GW, Roberts GD. Emerging fungal diseases: the importance of the host. Clin Lab Med 2004;24:691-719, vi-vii.
62. Reboli A.C., Rotstein C., Pappas P.G., Chapman S.W., Kett D.H., Kumar D., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356:2472-2482.
63. Richardson M., Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008, 14(Suppl. 4):5-24.
64. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am 2003, 17:113-134. viii.
65. Singh N., Alexander B.D., Lortholary O., Dromer F., Gupta K.L., John G.T., et al. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis 2008, 46:e12-e18.
66. Swanink C.M., Meis J.F., Rijs A.J., Donnelly J.P., Verweij P.E. Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J Clin Microbiol 1997, 35:257-260.
67. Upton A., Kirby K.A., Carpenter P., Boeckh M., Marr K.A. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007, 44:531-540.
68. Viscoli C., Girmenia C., Marinus A., Collette L., Martino P., Vandercam B., et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999, 28:1071-1079.
69. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327-360.
70. Wey S.B., Mori M., Pfaller M.A., Woolson R.F., Wenzel R.P. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988, 148:2642-2645.
71. Zaoutis T.E., Argon J., Chu J., Berlin J.A., Walsh T.J., Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005, 41:1232-1239.
72. Zaoutis T.E., Roilides E., Chiou C.C., Buchanan W.L., Knudsen T.A., Sarkisova T.A., et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J 2007, 26:723-727.